Recent

% | $
Quotes you view appear here for quick access.

Qiwi plc Message Board

holeinonein2002 8 posts  |  Last Activity: Jul 1, 2015 12:14 PM Member since: Aug 4, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    GBX call was very positive !!!

    by holeinonein2002 Jul 1, 2015 12:06 PM
    holeinonein2002 holeinonein2002 Jul 1, 2015 12:14 PM Flag

    Watch and learn my boy...get back to your paper route

  • holeinonein2002 by holeinonein2002 Jul 1, 2015 12:06 PM Flag

    They are acquisition minded and Trinity would be a good fit...Would not want to be short either TRN or GBX

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Jul 1, 2015 11:58 AM Flag

    Bend over shorts...This could rally hard

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Jun 12, 2015 1:09 PM Flag

    Nice recovery in a bad market

  • holeinonein2002 by holeinonein2002 Jun 2, 2015 9:48 AM Flag

    Hold on for some fun !!!

  • A non-human primate study confirmed earlier data of the nanoparticle technology’s targeting capability. Intravenous administration of the nanoparticles loaded with an RNA for a marker enzyme resulted in preferential expression in the lungs at two dosage strengths with no signs of toxicity across a panel of tests performed.
    A non-human primate study confirmed earlier data of the nanoparticle technology’s targeting capability. Intravenous administration of the nanoparticles loaded with an RNA for a marker enzyme resulted in preferential expression in the lungs at two dosage strengths with no signs of toxicity across a panel of tests performed.

    The stage is set for the next GEN-1 clinical trials to commence. Phase 1b results, which will be presented at the 2015 ASCO Annual Meeting convening on May 29th, show that liposomal delivery of an interleukin-12 gene therapy was well tolerated in combination with Doxil® by patients with ovarian cancer at the two doses tested.

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 May 22, 2015 10:44 AM Flag

    Smartest guys on the block...1st class shareholders

    Sentiment: Strong Buy

  • Buy Otonomy (OTIC) on Any Weakness Following Trial Results, Piper Jaffray Says

    May 22, 2015 7:46 AM
    Piper Jaffray analyst Joshua Schimmer has come out in defense of Otonomy (NASDAQ: OTIC), which is down sharply in pre-open trading after announced Phase 2b topline data for OTO-104 in Meniere's Disease, which "narrowly missed achieving statistical significance." Schimmer said while the trial did not reach statistical significance it still looked solid.

    "While the trial barely missed the primary endpoint of reduction in vertigo frequency with P value of 0.067, we believe the results indicate an active drug which should have a viable path forward," the analyst said. "The company will request a meeting with the FDA and plans to initiate 2 parallel P3 trials with at least one commenced by end-2015. We believe the P2b data (along with P1b data reported last year) demonstrate the benefit of OTO-104 in reducing vertigo and thus with proper trial designs, OTIC has a strong chance to succeed in the upcoming P3 trials. As such, we reiterate our OW rating with a PT of 46. We believe any weakness in the shares represents a compelling buying opportunity."

    For an analyst ratings summary and ratings history on Otonomy click here. For more ratings news on Otonomy click here.

    Shares of Otonomy closed at $31.05 yesterday.

    Categories
    Analyst Comments
    FDA
    Hot Comments
    Next Articles
    JPMorgan Downgrades Otonomy (OTIC) to Neutral
    May 22, 2015 6:36 AM
    Otonomy (OTIC) Announces OTO-104 Phase 2b Missed Primary Endpoint
    May 21, 2015 4:10 PM
    Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
    May 21, 2015 4:05 PM

    Sentiment: Strong Buy

QIWI
30.62+0.14(+0.46%)Jul 31 4:00 PMEDT